Physician profile
Melanie Mintzer
NPI 1528016300
$7,680.21
in general payments reported to CMS, 2019-2025
38 companies · $63.55 in 2025
The $63.55 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,130 · 2020: $1,428 · 2021: $3,433 · 2022: $625 · 2025: $63.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $63.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $63.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,991.43 | 2019-2025 | Wegovy |
| Amgen INC. | $693.04 | 2019-2021 | |
| Abbvie INC. | $557.81 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $469.39 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $385.18 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $276.45 | 2019-2021 | |
| Esperion Therapeutics, INC. | $270.41 | 2020-2021 | |
| Lilly USA, LLC | $252.65 | 2019-2022 | |
| Allergan, INC. | $243.32 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $189.95 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $189.94 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $162.83 | 2021 | |
| Amarin Pharma, INC. | $133.58 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $118.85 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.00 | 2019-2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $77.60 | 2019-2021 | |
| Pfizer INC. | $65.53 | 2019-2020 | |
| Antares Pharma, INC. | $48.38 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $42.65 | 2019-2020 | |
| Eisai INC. | $42.00 | 2020-2021 | |
| Astellas Pharma US INC | $39.62 | 2019-2020 | |
| Bausch Health US, LLC | $35.40 | 2019 | |
| Ibsa Pharma INC. | $32.48 | 2020-2021 | |
| Abbott Laboratories | $31.55 | 2021 | |
| Shire North American Group INC | $29.29 | 2019 | |
| Nestle Healthcare Nutrition INC. | $28.42 | 2021 | |
| Glaxosmithkline, LLC. | $26.04 | 2019-2020 | |
| Sanofi Pasteur INC. | $18.77 | 2019 | |
| Horizon Therapeutics Plc | $18.06 | 2020 | |
| Sunovion Pharmaceuticals INC. | $16.56 | 2020 | |
| Coopersurgical, INC. | $16.55 | 2022 | |
| Medtronic USA, INC. | $14.61 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $13.57 | 2021 | |
| Optos, INC. | $13.39 | 2020 | |
| Smith+Nephew, INC. | $12.43 | 2019 | |
| Amneal Pharmaceuticals LLC | $11.85 | 2021 | |
| Dexcom, INC. | $11.50 | 2020 | |
| Assertio Therapeutics, INC. | $11.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Mintzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.